Published • loading... • Updated
Oncolytics Biotech® Reports Accelerating Enrollment In
The randomized study is targeting about 60 patients and could support accelerated approval if response rates remain strong, the company said.
Summary by The Hamilton Spectator
7 Articles
7 Articles
Cambridge Times+5 Reposted by 5 other sources
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study
·Cambridge, Canada
Read Full Article
Coverage Details
Total News Sources7
Leaning Left5Leaning Right0Center1Last UpdatedBias Distribution83% Left
Bias Distribution
- 83% of the sources lean Left
83% Left
L 83%
C 17%
Factuality
To view factuality data please Upgrade to Premium
